High Intensity Focused Ultrasound (HIFU) - (0274) — MM 0274 | CIGNA Coverage Update

Cigna modified MM 0274 covering HIFU and MR-guided focused ultrasound procedures, effective December 16, 2025. Here's what billing teams need to know.

Cigna Healthcare updated its High Intensity Focused Ultrasound coverage policy under MM 0274 to address several conditions — including uterine fibroids, prostate cancer, bone metastases, and renal cancer. The revision directly affects five codes: CPT 51721, 55880, 55881, and 55882 for transurethral and transrectal prostate ablation, plus HCPCS C9734 for non-uterine focused ultrasound ablation with MR guidance. If your practice or facility bills any of these, the criteria under this updated policy govern what gets paid — and what gets denied.

Quick-Reference Table

Cigna HIFU Coverage Criteria and Medical Necessity Requirements 2025

The Cigna HIFU coverage policy under MM 0274 takes a conditional approach. These procedures are not blanket-covered. Each code carries a "considered medically necessary when criteria in the applicable section are met" designation. That means medical necessity documentation is not optional — it's the gate.

For prostate-related procedures specifically, CPT 55880 covers ablation of malignant prostate tissue via transrectal HIFU. CPT 55881 and 55882 cover transurethral thermal ultrasound ablation of prostate tissue, with MR imaging guidance built into the procedure. CPT 51721 covers insertion of the transurethral ablation transducer — the access component that makes thermal ultrasound delivery possible. All four require criteria compliance before Cigna considers them medically necessary.

HCPCS C9734 covers focused ultrasound ablation using MR guidance for indications other than uterine fibroids. This is where the policy gets interesting. The code's scope is broad — it captures non-uterine applications of MRgFUS — but Cigna's criteria control which of those applications actually qualify for reimbursement. Bill C9734 without documentation that maps to an approved indication, and you're looking at a claim denial.

Prior authorization requirements under this policy are a real operational concern. Given that HIFU procedures are high-cost and still considered investigational for several indications, prior auth workflows need to match the updated criteria. Don't assume a prior auth approved under the old policy version covers a claim billed after the December 16, 2025 effective date.

The billing guidelines for this coverage policy are explicit: the procedure must meet the criteria specific to the applicable clinical section. That's not vague — it means your documentation must tie the patient's clinical picture to the exact condition and circumstances Cigna recognizes as covered. Generic operative notes won't hold up.

Cigna HIFU Exclusions and Non-Covered Indications

MM 0274 addresses multiple body sites and conditions under the HIFU umbrella. Not all of them share the same coverage status. The policy specifically calls out uterine fibroids (leiomyomata) as a distinct category — note that HCPCS C9734 explicitly excludes uterine fibroid ablation in its code description. That's not an accident. Cigna has historically treated MRgFUS for uterine fibroids separately from other focused ultrasound applications.

The real issue here is scope creep in billing. HIFU technology is advancing fast, and payers like Cigna are drawing hard lines between what's established and what's still investigational. Bone metastasis treatment and renal cancer applications of HIFU sit in a gray zone for many payers. If your clinical team is using HIFU for indications beyond prostate cancer — where CPT 55880, 55881, and 55882 provide more specific code coverage — you need to verify those indications map to Cigna's criteria under MM 0274 before submitting.

If your facility performs MRgFUS for uterine fibroids, this policy is not your billing reference. Cigna manages that under separate coverage criteria. Using C9734 for uterine fibroid ablation will generate a denial — the code description excludes it by design.

Coverage Indications at a Glance

Cigna HIFU Billing Guidelines and Action Items 2025

1. Update your charge capture for CPT 51721, 55880, 55881, 55882, and HCPCS C9734 before December 16, 2025.
Flag these codes in your charge capture system with a notation that MM 0274 criteria apply. Anyone pulling these codes needs to know documentation requirements changed.

2. Pull your prior authorization workflows and align them to the updated criteria.
Authorizations requested under the old policy version may not reflect the current criteria. Confirm with Cigna that any open or pending authorizations are still valid for dates of service after December 16, 2025.

3. Separate your uterine fibroid MRgFUS billing from C9734.
HCPCS C9734 explicitly excludes uterine leiomyomata. If your billers have been using C9734 for fibroid procedures, stop. Find the correct code and policy path for that indication under Cigna's separate fibroid coverage criteria.

4. Audit recent claims for prostate HIFU to benchmark your approval rate.
Look at CPT 55880, 55881, and 55882 claims from the past 12 months. If your denial rate is higher than expected, the cause may be documentation gaps that the updated criteria will make worse — not better — without intervention.

5. Match clinical documentation to the specific criteria section for each indication.
MM 0274 covers multiple conditions. The criteria for prostate cancer HIFU (CPT 55880) are not the same as the criteria that govern C9734 for other non-uterine applications. Your documentation must map to the right section. Train your clinical documentation team on this distinction now.

6. If you bill C9734 for off-label or emerging HIFU applications, talk to your compliance officer before December 16, 2025.
The non-uterine MRgFUS category is where coverage disputes concentrate. Bone metastases and renal cancer applications are high-value procedures with inconsistent payer coverage across plans. Don't guess — confirm your indication qualifies under Cigna's criteria.

CPT, HCPCS, and ICD-10 Codes for HIFU Under MM 0274

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Covered HCPCS Codes (When Medical Necessity Criteria Are Met)

Note: ICD-10-CM diagnosis codes are not listed in the MM 0274 policy data. Map to the appropriate diagnosis code for each indication — malignant neoplasm of prostate, bone metastases, or renal malignancy — based on clinical documentation and standard coding guidelines.

A Note on the Prostate Codes

CPT 55881 and 55882 are often confused in billing because their descriptions are nearly identical at a glance. Both cover transurethral thermal ultrasound ablation of prostate tissue with MR imaging guidance. The distinction between them typically comes down to extent of ablation or session specifics — confirm with your coding team which applies to the procedure documented. Billing the wrong code between 55881 and 55882 invites a technical denial that has nothing to do with medical necessity and everything to do with code selection. Get this right before December 16, 2025.

CPT 51721, the transducer insertion code, is a separate billable component. It should not be bundled into the ablation code without verifying Cigna's bundling edits. Run this through your payer-specific edits in your clearinghouse before claims go out.